

Edgar Filing: TRANSGENOMIC INC - Form 8-K

TRANSGENOMIC INC
Form 8-K
August 17, 2006

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 15, 2006

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-30975	911789357
-----	-----	-----
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

12325 Emmet Street, Omaha, Nebraska	68164
-----	-----
(Address of principal executive offices)	(Zip Code)

(402) 452-5400

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING

On August 10, 2006, the Registrant's common stock began trading on the Nasdaq Capital Market (the "Capital Market"). On August 15, 2006, the Registrant was

Edgar Filing: TRANSGENOMIC INC - Form 8-K

notified by Nasdaq that it met all initial inclusion criteria for the Capital Market under Marketplace Rule 4310(c), except for the \$1.00 per share minimum bid price. Nasdaq provided the Registrant with a period of 180 calendar days, or until February 12, 2007, to attain compliance with this inclusion criteria. The Registrant may attain compliance with the minimum bid price requirement if, at any time before February 12, 2007, the bid price of the Registrant's common stock closes at \$1.00 per share or more for a minimum of 10 consecutive trading days. The Registrant has not determined an action or response to the notice as of the time of this filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

99.1 PRESS RELEASE DATED AUGUST 16, 2006

99.1 Press Release, dated August 16, 2006, announcing the Registrant's transfer to the Capital Market and that the Registrant has been provided an additional 180 calendar day period, or until February 12, 2007, to attain compliance with the minimum bid requirement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 16, 2006

TRANSGENOMIC, INC.

By: /s/ Michael Summers

Michael Summers,
Chief Financial Officer

align="bottom">\$98-30+; 4.003%

Yield to Maturity:
6.053%

Make-Whole Provision:
Treasury + 30 bps

Interest Payment Dates:
June 1 and December 1, commencing

December 1, 2008

Redemption Provisions:
No mandatory redemption provisions

Hubbell Incorporated may, at its option,
redeem the notes as described in the
Preliminary Prospectus Supplement, dated
May 28, 2008

Change of Control Offer:
As described in the Preliminary Prospectus
Supplement, dated May 28, 2008

Legal Format:
SEC-registered

Trade Date:
May 28, 2008

Settlement Date:
T+3; June 2, 2008

Joint Book-Running Managers	J.P. Morgan Securities Inc. Morgan Stanley & Co. Incorporated
Co-Managers:	Banc of America Securities LLC HSBC Securities (USA) Inc. BNY Mellon Capital Markets, LLC Wachovia Capital Markets, LLC
CUSIP:	443510AE2
ISIN:	US443510AE25
Use of Proceeds:	To repay approximately \$260 million of outstanding commercial paper borrowings and the remainder for general corporate purposes.
Ratings:	A3 (Moody's) A+ (S&P) A (Fitch)

A securities
rating is not a
recommendation
to buy, sell or
hold securities
and may be
subject to
revision or
withdrawal at
any time.

The offer and sale of the notes to which this final term sheet relates have been registered by Hubbell Incorporated by means of a registration statement on Form S-3 (SEC File No. 333-151206).

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling J.P. Morgan Securities Inc. collect at 1-212-834-4533 and Morgan Stanley & Co. Incorporated at 1-866-718-1649.